Objective: To investigate the efficacy of anti-tumor synergistic formula combined with tegafur on advanced colorectal cancer and the effect on quality of life and serum tumor markers

and explore their mechanism of action. Method: A total of 100 advanced colorectal cancer (ACC) patients diagnosed at our hospital between January 2013 and December 2015 were selected and randomly divided into two groups

with 50 cases in each group. The control group was treated with Gimeracil and Oteracil Porassium capsules

and the experiment group was treated with anti-tumor synergistic formula in addition to the therapy of control group. Peripheral blood T lymphocytes and related tumor markers were detected

the quality of life was assessed

and follow-up visits were made to record their respective survival time and compare the treatment effect and survival rate. Result: Compared with before treatment

CD3+

CD4+ and CD4+/CD8+ levels were lower (P<0.01)

and the CD8+ level was higher (P<0.01) in control group

and the CD3+

CD4+ and CD4+/CD8+ levels were higher (P<0.01)

and the CD8+ level was lower (P<0.01) in experiment group. Carcinoembryonic antigen (CEA)

carbohydrate antigen 242 (CA242) and carbohydrate antigen 19-9 (CA19-9) levels were lower in two groups (P<0.01)

the Quality of Life Questionnaire-Core 30 (QLQ-C30) scale function domain score was increased (P<0.01)

and the QLQ-C30 symptom domain score was lower (P<0.01). Compared with control group

the CD3+

CD4+ and CD4+/CD8+ levels were higher (P<0.01)

the CEA

CA242 and CA19-9 levels were lower (P<0.01)

the QLQ-C30 scale function domain score was increased (P<0.01)

and the QLQ-C30 symptom domain score was lower (P<0.01)

the objective response rate (ORR) was higher (P<0.05)

and the follow-up survival rate was higher (P<0.05) in experiment group. Conclusion: Anti-tumor synergistic formula combined with tegafur can improve the quality of life and survival of ACC

shows an ideal treatment effect

and is worth promotion.